GW Pharmaceuticals Stocks Soar After Successful Epilepsy Trial

GW Pharmaceuticals stocks have soared yet again after a clinical trial conducted on their product Epidiolex was deemed successful.

In a statement released by the British company, Epidiolex was found to have “induced a statistically significant improvement in reducing seizures” in patients with severe epilepsy during clinical trials.

After the news broke earlier this week, the company which is publicly traded saw their stocks rise by 16% to a record high 811 pence on the London Stock Exchange.

The next step for GW Pharma will be to seek approval from the U.S. Food and Drug Administration, to become the first approved cannabis extract in the States. This application is expected to go through during the first half of 2017.

With an international team of writers and over a decade of experience in the industry, aim to bring you the very latest in Medical Cannabis news from across the globe.


Have Your Say


Related News